3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
CNS
1
Conditions
Multiple Myeloma
5
Brain Neoplasms
3
Osteosarcoma
2
Neuroectodermal Tumors, Primitive
2
Neoplasms
2
Melanoma
2
Medulloblastoma
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rhabdomyosarcoma
1
Retinoblastoma
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Interventions
Cyclophosphamide
9
Topotecan
5
Temozolomide
5
Melphalan
5
Irinotecan
5
Busulfan
5
fludarabine
4
Granulocyte Colony-Stimulating Factor
4
Filgrastim
4
liposomal doxorubicin
3
fludarabine phosphate
3
cabozantinib
3
Vincristine
3
regorafenib
2
pegfilgrastim
2
Sirolimus
2
Doxorubicin
2
Bone Marrow Transplantation
2
trioctyl phosphine oxide
1
trifluridine tipiracil drug combination
1
thymoglobulin
1
talazoparib
1
selinexor
1
seclidemstat
1
racotumomab
1
poly ICLC
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
olaparib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Sarcoma, Ewing
×
Thalidomide
×
Clear all
NCT01661400
2024-01-31
ASCR
Washington University School of Medicine
Phase 1
Completed
14 enrolled